Vicki R Kee1. 1. Iowa Drug Information Service, University of Iowa College of Pharmacy, Iowa City, Iowa, USA. vicki-kee@uiowa.edu
Abstract
BACKGROUND: Clostridium difficile is a main cause of health care-associated infections. The incidence and severity have been increasing. Elderly persons are at an increased risk of morbidity and mortality from C. difficile infection (CDI). Relatively few advances have been made in the treatment of CDI since it was first identified as a cause of antibiotic-associated diarrhea more than 30 years ago. OBJECTIVE: This article reviews CDI and provides an update on its treatment, including recently published clinical practice guidelines and the recently approved drug, fidaxomicin. METHODS: English-language literature was identified through a search of PubMed (1966-October 2011), Iowa Drug Information Service (1966-October 2011), and International Pharmaceutical Abstracts (1970-October 2011). Key search terms included Clostridium difficile, Clostridium infections, pseudomembranous colitis, antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, elderly, geriatric, epidemiology, microbiology, diagnosis, risk factors, treatment, drug therapy, vancomycin, metronidazole, and fidaxomicin. RESULTS: Metronidazole and vancomycin remain the mainstays of CDI treatment. Current guidelines recommend oral metronidazole for initial mild to moderate episodes or first recurrence. Oral vancomycin is recommended for initial severe episodes, or first or second recurrence. Fidaxomicin was approved in 2011 for treatment of CDI, but its place in therapy has yet to be determined. Other antibiotics have been used with variable success. Saccharomyces boulardii is the only probiotic that has shown efficacy in CDI. Fecal transplants have been used successfully in some patients, but randomized studies are needed. Immune therapy with a vaccine and monoclonal antibodies is being studied in clinical trials. CONCLUSIONS: Treatment of CDI is challenging due to the limited number of drugs that have proven to be effective, concerns about antibiotic resistance, and recurring disease. The recent approval of fidaxomicin provides a new alternative. Immune therapy will likely play a greater role in the future. Copyright Â
BACKGROUND:Clostridium difficile is a main cause of health care-associated infections. The incidence and severity have been increasing. Elderly persons are at an increased risk of morbidity and mortality from C. difficileinfection (CDI). Relatively few advances have been made in the treatment of CDI since it was first identified as a cause of antibiotic-associated diarrhea more than 30 years ago. OBJECTIVE: This article reviews CDI and provides an update on its treatment, including recently published clinical practice guidelines and the recently approved drug, fidaxomicin. METHODS: English-language literature was identified through a search of PubMed (1966-October 2011), Iowa Drug Information Service (1966-October 2011), and International Pharmaceutical Abstracts (1970-October 2011). Key search terms included Clostridium difficile, Clostridium infections, pseudomembranous colitis, antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, elderly, geriatric, epidemiology, microbiology, diagnosis, risk factors, treatment, drug therapy, vancomycin, metronidazole, and fidaxomicin. RESULTS:Metronidazole and vancomycin remain the mainstays of CDI treatment. Current guidelines recommend oral metronidazole for initial mild to moderate episodes or first recurrence. Oral vancomycin is recommended for initial severe episodes, or first or second recurrence. Fidaxomicin was approved in 2011 for treatment of CDI, but its place in therapy has yet to be determined. Other antibiotics have been used with variable success. Saccharomyces boulardii is the only probiotic that has shown efficacy in CDI. Fecal transplants have been used successfully in some patients, but randomized studies are needed. Immune therapy with a vaccine and monoclonal antibodies is being studied in clinical trials. CONCLUSIONS: Treatment of CDI is challenging due to the limited number of drugs that have proven to be effective, concerns about antibiotic resistance, and recurring disease. The recent approval of fidaxomicin provides a new alternative. Immune therapy will likely play a greater role in the future. Copyright Â
Authors: Alla Aroutcheva; Julie Auclair; Martin Frappier; Mathieu Millette; Karen Lolans; Danielle de Montigny; Serge Carrière; Stephen Sokalski; William E Trick; Robert A Weinstein Journal: Probiotics Antimicrob Proteins Date: 2016-03 Impact factor: 4.609
Authors: Seong H Cho; Dae Woo Kim; Sun H Lee; Narasaiah Kolliputi; Seung J Hong; Lydia Suh; James Norton; Kathryn E Hulse; Sudarshan Seshadri; David B Conley; Robert C Kern; Bruce K Tan; Anju Peters; Leslie C Grammer; Robert P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2015-11 Impact factor: 6.914
Authors: Matthew Mossanen; Joshua K Calvert; Sarah K Holt; Andrew C James; Jonathan L Wright; Jonathan D Harper; John N Krieger; John L Gore Journal: J Urol Date: 2014-09-06 Impact factor: 7.450
Authors: Kevin W McConeghy; Andrew R Zullo; Christine W Lary; Tingting Zhang; Yoojin Lee; Lori Daiello; Douglas P Kiel; Sarah Berry Journal: J Am Med Dir Assoc Date: 2020-01-10 Impact factor: 4.669